These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 33244713)

  • 1. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
    Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
    Neurol Ther; 2023 Oct; 12(5):1709-1728. PubMed ID: 37458897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register.
    D'Amico E; Zanghì A; Romeo M; Cocco E; Maniscalco GT; Brescia Morra V; Paolicelli D; De Luca G; Galgani S; Amato MP; Salemi G; Inglese M; Confalonieri PA; Lus G; Avolio C; Gallo A; Vianello M; Onofrj M; Filippi M; Trojano M; Patti F
    Neurotherapeutics; 2021 Apr; 18(2):905-919. PubMed ID: 33528815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study.
    Moccia M; Affinito G; Marrazzo G; Ciarambino T; Di Procolo P; Confalonieri L; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
    Neurol Int; 2024 Mar; 16(2):394-405. PubMed ID: 38668126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
    Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
    BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
    Signoriello E; Signori A; Lus G; Romano G; Marfia GA; Landi D; Napoli F; D' Amico E; Zanghí A; Di Filippo PS; Caliendo D; Carotenuto A; Spiezia AL; Fantozzi R; Centonze D; Lucchini M; Mirabella M; Cocco E; Frau J; Maniscalco GT; Di Battista ME; Foschi M; Surcinelli A; Bonavita S; Abbadessa G; Pasquali L; Di Gregorio M; Ferrò MT; Sormani MP; Schiavetti I;
    Mult Scler Relat Disord; 2024 Jul; 87():105594. PubMed ID: 38718748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
    Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
    CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
    Zhornitsky S; Greenfield J; Koch MW; Patten SB; Harris C; Wall W; Alikhani K; Burton J; Busche K; Costello F; Davenport JW; Jarvis SE; Lavarato D; Parpal H; Patry DG; Yeung M; Metz LM
    PLoS One; 2015; 10(4):e0123824. PubMed ID: 25867095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey.
    Gross HJ; Watson C
    Neuropsychiatr Dis Treat; 2017; 13():1349-1357. PubMed ID: 28572730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study.
    Rog D; Brownlee W; Carod-Artal FJ; Kalra S; Barker N; Lowndes C; Pendlebury J; Leclerc S; Amin A; Ashton L; Evans H; De Cock E
    Mult Scler Relat Disord; 2024 Feb; 82():105380. PubMed ID: 38183696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis.
    Graille-Avy L; Boutiere C; Rigollet C; Perriguey M; Rico A; Demortiere S; Durozard P; Hilezian F; Vely F; Bertault-Peres P; Pelletier J; Maarouf A; Audoin B
    Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200231. PubMed ID: 38626360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
    Burks J; Marshall TS; Ye X
    Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario.
    Lorefice L; Mellino P; Frau J; Coghe G; Fenu G; Cocco E
    Neurol Sci; 2024 Aug; 45(8):3951-3959. PubMed ID: 38472551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
    Portaccio E; Fonderico M; Iaffaldano P; Pastò L; Razzolini L; Bellinvia A; De Luca G; Ragonese P; Patti F; Brescia Morra V; Cocco E; Sola P; Inglese M; Lus G; Pozzilli C; Maimone D; Lugaresi A; Gazzola P; Comi G; Pesci I; Spitaleri D; Rezzonico M; Vianello M; Avolio C; Logullo FO; Granella F; Salvetti M; Zaffaroni M; Lucisano G; Filippi M; Trojano M; Amato MP;
    JAMA Neurol; 2022 Sep; 79(9):869-878. PubMed ID: 35877104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis.
    López-Caneda C; Pérez-Haro MJ; Sánchez-Franco C; Álvarez-Rodríguez E; Aguado-Valcárcel M; Marcos-Bobillo M; González-Suarez I
    Mult Scler Relat Disord; 2023 Oct; 78():104909. PubMed ID: 37603928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.